Diabetes mellitus as a prothrombotic condition

Journal of Internal Medicine - Tập 262 Số 2 - Trang 157-172 - 2007
Peter J. Grant1
1From the Academic Unit of Molecular Vascular Medicine, Leeds Institute for Genetics, Health and Therapeutics, Faculty of Medicine and Health, University of Leeds, Leeds, UK

Tóm tắt

Abstract.Diabetes mellitus (DM) is characterized by fasting hyperglycaemia and a high risk of atherothrombotic disorders affecting the coronary, cerebral and peripheral arterial trees. The risk of myocardial infarction (MI) is 3‐5 fold higher in Type 2 DM and a DM subject with no history of MI has the same risk as a non‐DM subject with a past history of MI. In total around 70% of deaths are vascular with poorer outcomes to both acute events and cardiological interventions. It was proposed that clustering of vascular risk factors (hyperinsulinaemia, dysglycaemia, dyslipidaemia and hypertension) around insulin resistance (IR) accounted for the increase in risk with Type 2 DM. The importance of this became apparent with the recognition that risk clustering occurs in normoglycaemic and impaired glucose tolerance (IGT) subjects with IR, in total around 25% of the population in addition to long‐standing Type 1 subjects with renal disease. Evidence indicates that thrombotic risk clustering also occurs in association with IR, suppression of fibrinolysis due to elevated concentrations of the fibrinolytic inhibitor, plasminogen activator inhibitor‐1 (PAI‐1) is invariable with IR and there is evidence that this is regulated by the effects of triglyceride on the PAI‐1 gene promoter. Other studies indicated that prothrombotic risk (coagulation factors VII, XII and fibrinogen) also associates with the IR syndrome. The development of endothelial cell dysfunction with suppression of nitric oxide and prostacyclin synthesis, combined with platelet resistance to the anti‐aggregatory effects of these hormones leads to loss of control over platelet activation. In addition, hyperglycaemia and glycation have marked effects on fibrin structure function, generating a clot which has a denser structure, resistant to fibrinolysis. The combination of increased circulating coagulation zymogens, inhibition of fibrinolysis, changes in fibrin structure/function and alterations in platelet reactivity creates a thrombotic risk clustering which underpins the development of cardiovascular disease.

Từ khóa


Tài liệu tham khảo

10.2337/diab.37.12.1595

10.1056/NEJM199901143400207

10.1038/35025203

10.1056/NEJM198010163031601

10.1016/0002-8703(84)90684-7

10.1016/0021-9150(76)90116-7

10.1161/01.ATV.9.1.109

10.1016/0021-9150(79)90033-9

Bini A, 1987, Immunohistochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions, Blood, 69, 1038, 10.1182/blood.V69.4.1038.1038

10.1002/path.1711590203

10.1161/01.CIR.101.9.948

10.1024/0301-1526.32.3.139

10.1161/01.CIR.0000025404.78001.D8

10.1016/S0735-1097(01)01746-6

10.1111/j.1476-5381.1993.tb13873.x

10.1172/JCI1065

10.1172/JCI118709

10.2337/diabetes.50.1.159

10.1161/01.CIR.101.15.1780

10.1016/S0889-8529(05)70223-1

10.1016/j.amjcard.2004.01.009

10.1016/S0895-7061(01)02322-6

10.2337/diacare.26.7.2119

10.1016/S0002-9149(03)00611-8

10.1161/01.CIR.102.7.716

10.1172/JCI119636

10.1161/01.ATV.19.4.972

10.1097/00004872-200207000-00001

10.1161/01.CIR.100.25.2473

Lind S, 2003, Blood. Principles and Practice of Hematology, 959

Juhan‐Vague I, 1989, Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin, Thromb Haemost, 61, 370, 10.1055/s-0038-1646598

Mansfield M, 1997, PAI‐1 concentrations in first degree relatives of patients with non‐insulin dependent diabetes: metabolic and genetic associations, Thromb Haemost, 77, 357, 10.1055/s-0038-1655968

10.1161/01.CIR.94.9.2171

10.1016/S0140-6736(00)03541-8

10.1375/136905203321536281

10.2337/diab.44.4.369

Kruithof E, 1988, Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects, Fibrinolysis, 2, 59

10.1016/S0268-9499(95)80015-8

10.1136/bmj.291.6495.573

10.1136/hrt.59.5.535

10.1161/01.ATV.9.3.362

10.1161/01.CIR.94.9.2057

10.1016/S0140-6736(87)93050-9

10.1093/aje/152.10.897

10.1161/01.ATV.13.12.1865

10.1016/0026-0495(86)90209-X

10.1016/0026-0495(90)90164-8

10.1111/j.1365-2796.1990.tb00157.x

Juhan‐Vague I, 1987, Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1, Diab Metab, 13, 331

10.1016/0021-9150(89)90062-2

10.1007/BF00400356

10.1001/jama.283.2.221

10.1161/01.ATV.19.3.562

10.2337/diabetes.51.4.1131

10.1161/CIRCULATIONAHA.106.616177

Vague P, 1987, Metformin decreased the high plasminogen activator inhibitor capacity, plasma insulin and triglycerides in non diabetic obese subjects, Thromb Haemost, 57, 326, 10.1055/s-0038-1651126

10.1016/0268-9499(90)90369-U

10.1016/0268-9499(90)90375-T

10.2337/diabetes.55.04.06.db05-1076

10.1172/JCI115440

Kooistra T, 1989, Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes, Thromb Haemost, 62, 723, 10.1055/s-0038-1646891

Padayattay S, 1993, The effects of insulin‐like growth factor‐1 on plasminogen activator inhibitor 1 synthesis and secretion: results from in vitro and in vivo studies, Thromb Haemost, 70, 1009, 10.1055/s-0038-1649716

10.1016/0268-9499(90)90367-S

10.1161/01.ATV.13.12.1822

10.1042/cs0790513

10.1016/0268-9499(93)90017-P

10.2337/diab.43.1.104

10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.0.CO;2-G

10.1097/00019501-199611000-00004

10.2337/diab.47.2.290

10.2337/diab.46.5.860

10.1023/A:1013960416302

10.1111/j.1432-1033.1985.tb08911.x

10.1111/j.1365-2796.1994.tb01097.x

Carter A, 1998, Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease, Thromb Haemost, 80, 632

10.1161/01.CIR.96.3.761

10.1016/S0021-9150(99)00030-1

10.1016/S0140-6736(86)90111-X

10.1161/01.ATV.14.1.54

10.1161/01.CIR.96.4.1102

Scarabin P‐Y, 1998, Associations of fibrinogen, factor VII and PAI‐1 with baseline findings among 10500 male participants in a prospective study of myocardial infarction. The Prime Study, Thromb Haemost, 80, 749, 10.1055/s-0037-1615353

10.1016/0140-6736(93)92062-X

10.1016/0021-9150(91)90167-2

Balleisen L, 1985, Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using, and menopause, Thromb Haemost, 54, 475, 10.1055/s-0038-1657877

Balleisen L, 1985, Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population – II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions, Thromb Haemost, 54, 721, 10.1055/s-0038-1660106

Heywood D, 1996, Factor VII gene polymorphisms, factor VIIc levels and features of insulin resistance in non‐insulin dependent diabetes mellitus, Thromb Haemost, 75, 401, 10.1055/s-0038-1650286

10.1056/NEJM198811173192001

10.1161/01.ATV.9.6.928

Krolewski A, 1981, Prevalence of diabetes mellitus, coronary heart disease and hypertension in the families of insulin dependent and insulin independent diabetes, Diabetologia, 21, 520, 10.1007/BF00281541

10.2337/diacare.18.7.1020

10.1111/j.1365-2141.1985.tb02991.x

10.1016/0021-9150(89)90104-4

10.1016/0021-9150(89)90169-X

10.1016/S0140-6736(83)91849-4

Carvalho de Sousa J, 1989, Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity, Haemostasis, 19, 125

10.1136/jcp.41.9.940

10.1016/0021-9150(91)90212-L

10.1161/01.ATV.16.1.77

Carvalho A, 1978, Activation of the kallikrein system in hyperbetalipoproteinemia, J Lab Clin Med, 91, 117

10.1172/JCI109543

10.1146/annurev.cb.06.110190.001245

Blann A, 1991, Increased circulating levels of von Willebrand Factor antigen in smokers may be due to lipid peroxides, Med Sci Res, 19, 535

Blann A, 1993, von Willebrand factor and endothelial damage in essential hypertension, J Hum Hypertens, 7, 107

10.1016/S0140-6736(94)91047-2

10.3109/00365516209079703

10.1136/hrt.53.3.265

10.1056/NEJM199503093321003

10.1136/hrt.66.5.351

10.1016/0049-3848(86)90385-3

10.1136/hrt.59.3.287

10.1016/S0140-6736(80)91498-1

Conlan M, 1993, Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities Study, Thromb Haemost, 70, 380, 10.1055/s-0038-1649589

10.1161/01.ATV.14.5.686

10.2337/diab.46.2.S9

10.1016/S0002-9149(03)00612-X

10.1146/annurev.bi.53.070184.001211

Lowe G, 1980, Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia, Thromb Haemost, 42, 1503

10.1055/s-0037-1613566

10.7326/0003-4819-118-12-199306150-00008

10.1016/0021-9150(88)90303-6

Korsan‐Bengtsen K, 1972, Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. Relations of the variables to ‘risk factors’ for myocardial infarction, Thromb Diath Haemorrh, 28, 99

10.1210/jc.85.9.3121

10.1097/00001721-199609000-00002

10.1007/BF02592301

Avellone G, 1994, Blood coagulation and fibrinolysis in obese NIDDM patients, Diabetes Res, 25, 85

Collier A, 1992, Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria, Diabetes, 41, 909, 10.2337/diab.41.8.909

10.1016/0021-9150(95)05647-5

10.1111/j.1464-5491.1991.tb01604.x

10.1136/bmj.2.6196.964

10.1111/j.1464-5491.1990.tb01435.x

10.1016/S1056-8727(00)00075-1

10.1016/S1056-8727(02)00204-0

10.1007/BF02374497

Christe M, 1984, Fifteen coagulation factors and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy, Thromb Haemost, 52, 138, 10.1055/s-0038-1661158

10.2337/diacare.19.2.157

10.1007/s001250051064

10.1046/j.1464-5491.2000.00384.x

10.7326/0003-4819-125-8-199610150-00005

Jain A, 2001, Hyperfibrinogenaemia in patients of diabetes mellitus in relation to glycaemic control and urinary albumin excretion rate, J Assoc Physicians India, 49, 225

Reid H, 2000, The influence of persistent hyperglycaemia on hyperfibrinogenaemia and hyperviscosity in diabetes mellitus, West Indian Med J, 49, 281

10.1111/j.1464-5491.1993.tb00169.x

10.1001/archinte.158.22.2485

Becker A, 2003, Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin, Neth J Med, 61, 129

Knobl P, 1994, Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients, Thromb Haemost, 71, 692, 10.1055/s-0038-1642506

Fanghanel G, 1998, Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes, Rev Invest Clin, 50, 389

10.1161/01.ATV.17.10.2103

10.1055/s-0037-1614210

10.1016/S0021-9258(19)44312-3

10.1055/s-0037-1614250

10.1046/j.1464-5491.2003.00958.x

10.2337/diacare.23.5.703

10.1016/0140-6736(91)91164-P

Schmeling A, 1996, Phenotype change in polymorphic plasma proteins following liver transplantation, Exp Clin Immunogenet, 13, 78

10.1182/blood.V68.6.1272.1272

10.1182/blood-2003-07-2247

Gabriel D, 1992, The effect of fibrin structure on fibrinolysis, J Biol Chem, 267, 24259, 10.1016/S0021-9258(18)35759-4

10.1055/s-0038-1650618

10.1161/01.HYP.12.6.530

10.1172/JCI109375

10.1016/S1056-8727(01)00196-9

10.2337/diacare.21.1.121

10.1111/j.1365-2362.1982.tb00686.x

10.1161/hq0102.101546

10.2337/diacare.24.8.1476

Kroll M, 1989, Biochemical mechanisms of platelet activation, Blood, 74, 1181, 10.1182/blood.V74.4.1181.1181

10.1007/s001250050958

10.1016/S0026-0495(96)90122-5

10.1291/hypres.20.225

10.1016/0002-9343(81)90412-5

10.2337/db05-1543

10.1161/01.ATV.17.11.2885

10.1016/S0168-8227(99)00094-7

10.1016/j.metabol.2006.02.019

10.1016/S0735-1097(01)01555-8

10.1093/ndt/gfg619

10.1007/s00125-005-1742-2

10.1007/s00125-006-0197-4

10.1161/01.CIR.99.2.224

Hangaishi M, 1997, Advanced glycation end products enhance the aggregation of human platelets in vitro, Circulation, 96, 665